Upstream Bio
Upstream Bio's revenue rose 20.4% to $3 million in fiscal 2025. Its operating margin was −5,618.8%, down from −3,281.2% a year earlier. Free cash flow was −$133 million. The diluted share count rose 293.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Upstream Bio lost money in fiscal 2025: a net loss of $143 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 110 | 470 | 342 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 18.0x | 44.6x | 26.1x |
| Quick ratio | 18.0x | 44.6x | 26.1x |
Cash flow
Projections
Project Upstream Bio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Upstream Bio shares on the open market, and 5 insiders sold $104,799.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Everett Rand SutherlandChief Executive Officer, Director | Sold | 2,095 | $5.49 | $11,502 | Form 4 |
| Sep 16, 2026 | Aaron DeykinChief Medical Officer | Sold | 895 | $5.49 | $4,914 | Form 4 |
| Sep 16, 2026 | Michael GrayCFO and COO | Sold | 853 | $5.49 | $4,683 | Form 4 |
| Sep 16, 2026 | Adam HoughtonChief Business Officer | Sold | 700 | $5.49 | $3,843 | Form 4 |
| Sep 16, 2026 | Allison AmbroseGeneral Counsel | Sold | 485 | $5.49 | $2,663 | Form 4 |
| Jun 16, 2026 | Everett Rand SutherlandChief Executive Officer, Director | Sold | 2,095 | $6.10 | $12,780 | Form 4 |
| Jun 16, 2026 | Aaron DeykinChief Medical Officer | Sold | 895 | $6.10 | $5,460 | Form 4 |
| Jun 16, 2026 | Michael GrayCFO and COO | Sold | 853 | $6.10 | $5,203 | Form 4 |
| Jun 16, 2026 | Adam HoughtonChief Business Officer | Sold | 700 | $6.10 | $4,270 | Form 4 |
| Jun 16, 2026 | Allison AmbroseGeneral Counsel | Sold | 477 | $6.10 | $2,910 | Form 4 |
| Mar 16, 2026 | Everett Rand SutherlandChief Executive Officer, Director | Sold | 2,093 | $9.29 | $19,444 | Form 4 |
| Mar 16, 2026 | Aaron DeykinChief Medical Officer | Sold | 894 | $9.29 | $8,305 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −2,518.7% | −4,655.1% |
| Altman Z'' | 45.58 | 25.63 |
| Accruals ratio | −1.2% | −2.4% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Upstream Bio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Upstream Bio | FY25 | 20.4% | −5,618.8% | −4,675.5% | — | — | — | |
| Cartesian Therapeutics | FY25 | −92.8% | −5,127.1% | −2,838.6% | — | — | — | Compare |
| GeoVax Labs | FY25 | −37.1% | −869.3% | −863.8% | — | — | 2 | Compare |
| CAMP4 Therapeutics | FY25 | 436.5% | −1,502.4% | −852.8% | — | — | — | Compare |
| Marker Therapeutics | FY25 | −46.2% | −363.4% | — | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 2 | 2 | 3 |
| Revenue growth | — | −0.4% | 20.4% |
| Gross profit | — | — | — |
| Research and development | 32 | 63 | 137 |
| Operating income | −40 | −78 | −160 |
| Net income | −20 | −63 | −143 |
| Diluted EPS (US$) | −12.95 | −5.58 | −2.66 |
| Diluted shares (millions) | 3 | 14 | 54 |
| Cash flow | |||
| Cash from operations | −38 | −59 | −133 |
| Capital expenditure | 0 | 0 | 0 |
| Free cash flow | −38 | −60 | −133 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 3 | 6 | 10 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 110 | 470 | 342 |
| Debt incl. finance leases | — | — | — |
| Total assets | 117 | 482 | 354 |
| Total liabilities | 9 | 12 | 14 |
| Shareholders' equity | −123 | 470 | 340 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −1,685.5% | −3,281.2% | −5,618.8% |
| Net margin | −862.9% | −2,650.0% | −5,026.0% |
| Free cash flow margin | −1,599.6% | −2,518.3% | −4,675.5% |
| Rule of 40 (growth + FCF margin) | — | −2,518.7% | −4,655.1% |
| Return on capital | — | — | — |
| Return on equity | — | −36.2% | −35.4% |
| Return on assets | — | −21.0% | −34.3% |
| Net debt to EBITDA | — | — | — |